Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Provention Bio Inc

(NASDAQ: PRVB)
Add to Portfolio
+0.50 (+8.31%)
as of Oct 18, 2019

Last 6.52
Change +0.50 (+8.31%)
Open 6.00
Prev. Close 6.02
Today's Range
6.00
6.78
52wk Range
1.52
22.82
Volume 400,300
Avg Volume 489,155
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
PRVB +8.31% -27.07% +92.90%
DJIA -0.95% +1.49% +5.48%
S&P 500 -0.39% +1.64% +7.85%

Key Statistics

Annual EPS -0.93
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 236,910
Weighted Alpha -15.00
Standard Deviation +1.45
Profit Margin N/A
Beta 5.79

Growth Rates

YTD +268.36%
1-Year +94.63%

Opinion

Sell Hold Buy

Recent Headlines

Sean Doherty Joins Provention Bio Board of Directors

PRNW - Thu Sep 26, 07:00AM EDT
OLDWICK, N.J. , Sept. 26, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appoi(full story)
PRVB: 6.52 (+0.50)

Provention Bio to Present at the 2019 Cantor Global

PRNW - Wed Sep 25, 07:00AM EDT
OLDWICK, N.J. , Sept. 25, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that managemen(full story)
PRVB: 6.52 (+0.50)

Provention Bio Reiterates Regulatory Strategy for

PRNW - Tue Sep 24, 07:00AM EDT
OLDWICK, N.J. , Sept. 24, 2019 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated it(full story)
PRVB: 6.52 (+0.50)

Provention Bio Announces Pricing of $40 Million Public

PRNW - Wed Sep 18, 08:26PM EDT
OLDWICK, N.J. , Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing o(full story)
PRVB: 6.52 (+0.50)

Provention Bio Announces Proposed Public Offering of

PRNW - Wed Sep 18, 04:14PM EDT
OLDWICK, N.J. , Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it (full story)
PRVB: 6.52 (+0.50)